NEW DELHI: The Bharat Biotech’s Covaxin has been listed under the US Centers for Disease Control (CDC)’s “Accepted COVID-19 Vaccines” for international travellers.
Now those inoculated with the Bharat Biotech-manufactured jab will not have to self-isolate after arrival in US.
The United States has given its approval for travellers who have received both doses of Covaxin to enter the country beginning November 8 Lifting up the historic restrictions that had barred much of the world from entering the country for as long as 21 months.
The development has come after the World Health Organization (WHO) has approved emergency use listing (EUL) to Covaxin, adding to a growing range of vaccines certified by WHO for the prevention of COVID-19.
As per reports, Covaxin was found to be effective against symptomatic COVID-19 in 77.8% of cases and 65.2 percent of the time against the novel Delta variant in 65.2 percent of cases. The Company announced in June that it has concluded the final analysis of Covaxin efficacy from Phase 3 trials.
Meanwhile, the UK government also announced that it would add Covaxin to its list of approved COVID-19 vaccines for international travellers from November 22.
Check the requirement for proof of COVID-19 vaccination for air passengers in US:
- Those who are non-U.S. citizens who is a nonimmigrant (not a U.S. citizen, U.S. national, lawful permanent resident, or traveling to the United States on an immigrant visa) will need to show proof of being fully vaccinated against COVID-19 before traveling by air to the United States from a foreign country.
- Some categories of noncitizen, nonimmigrants are excepted from this requirement. If they meet the criteria for one of these categories, they will need to fulfill additional requirements to travel by air to the United States.
- Before boarding a flight to the United States, all air passengers ages 2 and up, regardless of citizenship or immunisation status, must show a negative result of a COVID-19 virus test or documentation of recovery from COVID-19.
Check the requirements to be considered fully vaccinated
1.14 days after receiving a single-dose vaccine that has been approved.
2. 14 days following the second dose of a 2-dose series that has been approved.
3. 14 days after receiving the full series of an approved COVID-19 vaccination in a clinical trial (not placebo).
4. 14 days after receiving the whole series (not placebo) of a Novavax (or Covavax) COVID-19 vaccination in a phase 3 clinical trial.
5. 14 days after receiving two doses of any “mix-and-match” combination of approved COVID-19 vaccinations given at least 17 days apart.
Support our brand of fearless and investigative journalism: